Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL4406902 | 0.98 | CYP1A2 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL18824897 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL163442 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3258 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL388563 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3259 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL163443 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL995910 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL8080341 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL388561 | 0.98 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7060803-B2 | Metal complex-protein composite and hydrogenation catalyst | NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) | 2006-06-13 | — | — | US | claimed |
| US-20220144895-A1 | DE NOVO DESIGN OF TUNABLE PH-DRIVEN CONFORMATIONAL SWITCHES | UNIVERSITY OF WASHINGTON | 2022-05-12 | — | — | US | disclosed |
| WO-2020215054-A1 | DE NOVO DESIGN OF TUNABLE PH-DRIVEN CONFORMATIONAL SWITCHES | UNIVERSITY OF WASHINGTON (US) | 2020-10-22 | — | — | WO | disclosed |
| US-10023536-B2 | Suprametallogels and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170073311-A1 | SUPRAMETALLOGELS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-03-16 | — | — | US | disclosed |
| US-9447129-B2 | Suprametallogels and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| CN-105829519-A | Stable liquid compositions comprising enzymes and peroxides | 阿科玛股份有限公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20150225438-A1 | SUPRAMETALLOGELS AND USES THEREOF | NATIONAL SCIENCE FOUNDATION | 2015-08-13 | — | — | US | disclosed |
| WO-2015120391-A1 | SUPRAMETALLOGELS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-08-13 | — | — | WO | disclosed |
| EP-2025757-A2 | Polymeric immunoglobulin receptor-mediated gene transfer | Case Western Reserve University (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1006797-A4 | SERPIN ENZYME COMPLEX RECEPTOR-MEDIATED GENE TRANSFER | UNIV CASE WESTERN RESERVE (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6200801-B1 | A POLYCATION AND A BINDING MOIETY OF DEFINED AMINO ACID SEQUENCE CAPABLE OF BINDING TO A SERPIN ENZYME COMPLEX RECEPTOR FOR TARGETED GENE DELIVERY; GENE THERAPY; ANTISENSE AGENTS | CASE WESTERN RESERVE UNIVERSITY | 2001-03-13 | — | — | US | disclosed |
| EP-1006797-A1 | SERPIN ENZYME COMPLEX RECEPTOR-MEDIATED GENE TRANSFER | Case Western Reserve University (US) | 2000-06-14 | — | — | EP | disclosed |
| US-5972901-A | MAKING A COMPOSITION FOR DELIVERING AN OLIGONUCLEOTIDE TO A MAMMALIAN CELL BY PROVIDING A PEPTIDE TARGET BINDING MOIETY BEING CAPABLE OF BINDING TO A SERPIN ENZYME COMPLEX RECEPTOR, POLYLYSINE, AN OLIGONUCLEOTIDE VECTOR; CONJUGATING, COUPLING | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1997046100-A1 | SERPIN ENZYME COMPLEX RECEPTOR-MEDIATED GENE TRANSFER | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225438-A1 | SUPRAMETALLOGELS AND USES THEREOF | PDCD1LG2, PDCD2L, PYGL | SLC7A5 384/4885CYP3A4 4117/4885CYP1A2 3238/4885 |
| US-10023536-B2 | Suprametallogels and uses thereof | PDCD1LG2, PDCD2L, PYGL | SLC7A5 384/4885CYP3A4 4117/4885CYP1A2 3238/4885 |
| US-20170073311-A1 | SUPRAMETALLOGELS AND USES THEREOF | PDCD1LG2, PDCD2L, PYGL | SLC7A5 384/4885CYP3A4 4117/4885CYP1A2 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.